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Summary
Family-based tests of association provide the opportu-
nity to test for an association between a disease and a
genetic marker. Such tests avoid false-positive results
produced by population stratification, so that evidence
for association may be interpreted as evidence for link-
age or causation. Several methods that use family-based
controls have been proposed, including the haplotype
relative risk, the transmission-disequilibrium test, and
affected family–based controls. However, because these
methods require genotypes on affected individuals and
their parents, they are not ideally suited to the study of
late-onset diseases. In this paper, we develop several fam-
ily-based tests of association that use discordant sib pairs
(DSPs) in which one sib is affected with a disease and
the other sib is not. These tests are based on statistics
that compare counts of alleles or genotypes or that test
for symmetry in tables of alleles or genotypes. We de-
scribe the use of a permutation framework to assess the
significance of these statistics. These DSP-based tests
provide the same general advantages as parent-offspring
trio–based tests, while being applicable to essentially any
disease; they may also be tailored to particular hypoth-
eses regarding the genetic model. We compare the sta-
tistical properties of our DSP-based tests by computer
simulation and illustrate their use with an application
to Alzheimer disease and the apolipoprotein E poly-
morphism. Our results suggest that the discordant-alleles
test, which compares the numbers of nonmatching al-
leles in DSPs, is the most powerful of the tests we con-
sidered, for a wide class of disease models and marker
types. Finally, we discuss advantages and disadvantages
of the DSP design for genetic association mapping.
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Introduction
In association-mapping studies, we seek to localize or
identify disease genes by searching for dependence be-
tween the disease of interest and one or more genetic
markers. To date, association-mapping studies have fo-
cused primarily on assessing the role of candidate genes,
genes believed likely to play a role in disease etiology
on the basis of biochemical, physiological, or other avail-
able information. In the near future, association map-
ping may assume substantial or even primary impor-
tance in genomewide disease-mapping efforts (Risch and
Merikangas 1996).
Classically, association-mapping studies have been
used to test for disease-marker associations in a case-
control design in which alleles or genotype frequencies
in a random sample of affected individuals (cases) are
compared with those in a random sample of unaffected
individuals (controls). With this case-control design, in-
terpretation of evidence for association can be problem-
atic; while such evidence may reflect linkage or causa-
tion, it also may reflect population differences between
cases and controls.
To avoid this difficulty, several investigators have de-
veloped methods that employ family-based controls
(Falk and Rubenstein 1987; Ott 1989; Knapp et al.
1993; Spielman et al. 1993; Thomson 1995; Schaid
1996; Spielman and Ewens 1996). These methods re-
quire genotype data on affected individuals and their
parents and make use of the transmission information
in these parent-offspring trios, instead of requiring an
unrelated sample of controls. For these trio-based meth-
ods, in the absence of meiotic segregation distortion,
positive results reflect evidence for linkage due to either
linkage disequilibrium or causation and cannot arise as
a result of population differences between cases and con-
trols. These methods have proved useful for early-onset
diseases for which parents are routinely available for
sampling. However, for late-onset diseases, such as
non–insulin dependent diabetes mellitus (NIDDM), Alz-
heimer disease, heart disease, and many forms of cancer,
the requirement for parents cannot always be met and,
when met, may result in a sample of cases with unusually
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Table 1
Allele-Counting Schemes for DSPs
CASE SIB GENOTYPES
ALLELES COUNTED
Scheme 1 Scheme 2
1 11 11 1,1 1,1 ) )
2 11 12 1,1 1,2 1 2
3 11 22 1,1 2,2 1,1 2,2
4 11 23 1,1 2,3 1,1 2,3
5 12 12 1,2 1,2 ) )
6 12 13 1,2 1,3 2 3
7 12 34 1,2 3,4 1,2 3,4
NOTE.—1, 2, 3, and 4 represent distinct alleles at the marker locus.
early–onset disease not representative of the disease pop-
ulation as a whole.
In this paper, we describe several tests of association
based on a discordant–sib-pair (DSP) design. In this de-
sign, we use families with at least one affected and one
unaffected sib; parents and additional sibs are not re-
quired. Our tests contrast the alleles or genotypes present
in the affected and unaffected sibs, either by comparison
of counts or tests of symmetry. For several of the tests,
dependence of the alleles or genotypes of the DSPs results
in test statistics of unknown distribution. To overcome
this problem, we use permutation methods (e.g., see Ef-
ron and Tibshirani 1993) to assess statistical signifi-
cance. Because of the matching inherent in the DSP de-
sign, each of these tests has the same advantage as the
trio-based methods: evidence for association can be
taken as evidence for linkage or causation.
To compare the power of our test statistics, we carried
out a simulation study in which a genetic disease was
partially determined by a genetic locus linked to a genetic
marker. Our results demonstrate that the discordant-al-
leles–test (DAT) statistic, which compares the numbers
of nonmatching marker alleles in the affected and un-
affected sibs, is the most powerful of the test statistics
we considered, for a broad class of genetic models. Sim-
ilar procedures were proposed by Clarke et al. (1956)
and more recently by Curtis (1997). To illustrate the use
of our tests, we analyzed 112 northern European Alz-
heimer disease DSPs genotyped for the apolipoprotein
E (ApoE) polymorphism. Our analysis confirms thewell-
established association between Alzheimer disease and
ApoE (Corder et al. 1993, 1994; Saunders et al. 1993),
further demonstrating the value of the DSP-based tests.
We conclude with a discussion of the advantages and
disadvantages of the DSP design and discuss topics for
future research.
Methods
Allele- and Genotype-Counting Statistics
We assume that N independent DSPs have been gen-
otyped for a marker with alleles. Under the as-m x 2
sumption of no disease-marker association, the counts
of the alleles in affected and unaffected sibs are expected
to be equal. To test for a disease-marker association, we
contrast the counts of marker alleles in the affected and
unaffected sibs. These counts may be of all alleles present
in the sibs or may include only those alleles discordant
in the two sibs. These two counting schemes are dis-
played in table 1. Scheme 1 is simpler and uses all alleles.
Scheme 2 uses only those marker alleles that differwithin
a pair; in so doing, it attempts to reduce the overmatch-
ing inherent in the DSP design (see Discussion).
Under either allele-counting scheme, let be then1j
count of marker allele j ( ) in the N affected1 X j X m
sibs, and let be the corresponding count in the Nn2j
unaffected sibs. To test for a disease-marker association,
we compute the Pearson homogeneity statistic for a
table:2 # m
2m ( )n  n1j 2j
AC  .i n  nj1 1j 2j
We call AC1 the “all-alleles statistic” and AC2 the “dis-
cordant-alleles statistic.” Analogous statistics GC1 and
GC2 compare the counts of all geno-M  m(m 1)/2
types in affected and unaffected sibs and of discordant
genotypes in affected and unaffected sibs, respectively.
Permutation Tests
Although these allele- and genotype-counting statistics
directly address the question of disease-marker associ-
ation, the dependence among the sibling alleles and gen-
otypes violates the assumption of independent obser-
vations in the (or ) table. Hence, the2 # m 2 # M
large-sample distribution of these statistics, under the
null hypothesis of no association, is not on (or2x m 1
) df. This problem is easily surmounted by use ofM 1
a permutation test (e.g., see Efron and Tibshirani 1993).
The basic idea of a permutation test is to choose a
family of permutations of the data such that the prob-
ability of each permutation is known, under the null
hypothesis; usually, all possible permutations are chosen
to be equally likely. The distribution of a test statistic is
then either determined by evaluating the statistic for all
possible permutations of the data or estimated by eval-
uating the statistic for a random sample of permutations.
The P value of the observed test statistic can be estimated
by the proportion of permutations for which the per-
muted-data test statistic is greater than the observed test
statistic. When the permuted-data test statistic exactly
equals that of the observed data, because of the discrete
distributions of our statistics, we may reasonably incre-
ment the count by rather than by 1.12
In the DSP case, we randomly interchange the affec-
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tion statuses of the sibs. Under the null hypothesis of no
association, this approach results in permutations of the
data that are equally likely. Permutation tests require
essentially no assumptions and, in principle, allow es-
timation of the distribution of any test statistic to any
desired level of accuracy; albeit, two applications of the
method to the same data may yield slightly different
estimates of the P value if a sample of permutations is
used instead of all possible permutations. Permutation
tests are computationally demanding, particularly if
small P values are to be estimated accurately, as is often
important in gene-mapping applications. Given current
computing power, this disadvantage is more aesthetic
than scientific.
Permuting DSP genotype pairs can be done in at least
three ways. First, for each permutation, we may switch
or not switch the phenotype labels of each DSP inde-
pendently, with probability . Second, we may build the12
table with entries equal to the number of DSPs ingij
which the affected sib has genotype i and the unaffected
sib has genotype j. Then, for each , we generate ai ! j
binomial random variable on  trials and prob-g gij ji
ability of success of . If the number of marker alleles12
is sufficiently small that the number of distinct marker-
genotype pairs is small in comparison to the number of
DSPs, the second approach is more efficient than the
first. Third, if the product
M1 M ( )  g  g  1i1 ji1 ij ji
is sufficiently small, the P valuemay be evaluated exactly,
by cycling through all sets of genotype counts that main-
tain the totals ( ) for all i and j.g  gij ji
Symmetry Statistics
Under the assumption of no disease-marker associa-
tion, the numbers of each genotype or allele are expected
to be equal in the affected and unaffected sibs. Thus,
tables of numbers of DSPs in which rows correspond to
the genotypes or alleles of affected sibs and the columns
to the genotypes or alleles of unaffected sibs are expected
to be symmetric. We propose several statistics that ex-
ploit this observation.
The simplest of these statistics compares the frequen-
cies of the genotypes in the affected and unaffected sibs.
Given no disease-marker association, the expected val-
ues , for all i and j, suggesting the classicE(g )  E(g )ij ji
symmetry statistic
2M1 M ( )g  gij ji
G   s g  gi1 ji1 ij ji
(Bowker 1948), where is the numberM  m(m 1)/2
of possible genotypes. For independent DSPs, the ge-
notype-symmetry statistic, Gs, is asymptotically distrib-
uted as x2 on df; the approximation to thisM(M 1)/2
asymptotic distribution generally is accurate if g ij
, for all i and j. When this condition is not met, ag 1 3ji
permutation framework again can be used to assess
significance.
Since the number of genotypes M may be large, mod-
est evidence for asymmetry due to a subset of the geno-
types may be swamped by the large number of com-
parisons. A possible solution is to consider alleles rather
than genotypes (for another solution, see “Pooling Al-
leles”). One allele-based symmetry approach is to let
be the number of DSPs in which the affected sib hasaij
at least one copy of allele i and the unaffected sib has
at least one copy of allele j. Given no disease-marker
association, the expected values , for all iE(a )  E(a )ij ji
and j, suggesting the statistic
2m1 m ( )a  aij ji
A  . s a  ai1 ji1 ij ji
The allele-symmetry statistic, As, has the advantage of
a smaller number of comparisons, since it is based on
alleles rather than genotypes. Because of the double
counting of marker heterozygous-homozygousDSPs, the
quadruple counting of marker heterozygous-heterozy-
gous DSPs, and the resulting dependent observations, As
is not distributed asymptotically as x2; however, a per-
mutation test can again be applied to assess significance.
A potentially useful modification is to weight the con-
tribution of each DSP to sum to 1. Thus, in calculating
the weighted allele-symmetry statistic Aws, the four allele
pairs of a heterozygous-heterozygous DSP are weighted
by , and the two allele pairs of a homozygous-heter-14
ozygous DSP are weighted by .12
Pooling Alleles
A prior hypothesis that suggests an association be-
tween disease and a specific (set of) marker alleles or
genotypes can easily be incorporated into our tests. For
example, the prior hypothesis that a single marker allele
is associated with disease can be incorporated into all
seven statistics by pooling all other marker alleles to-
gether. This reduces the effective number of alleles from
m to 2. Pooling based on a prior hypothesis regarding
a marker genotype can similarly be incorporated into
the genotype statistics GC1, GC2, or Gs. Pooling increases
the power to detect the hypothesized association (see
Results). Clearly, if it is hypothesized that more than one
allele is associated with disease, alternative pooling strat-
egies, such as the best subset of alleles or an ordering
of allele effect, could be employed.
For a marker with a moderate to large number of
alleles m, even given no prior hypothesis of association,
Boehnke and Langefeld: Discordant-Alleles Test for Association 953
Table 2
Characteristics of the Simulated Disease Models
Model K fDD fdd p ls
a
Dominant .05 .20 .025 .074 1.74
.50 .025 .027 3.23
.80 .025 .016 4.73
Additive .05 .20 .025 .143 1.37
.50 .025 .053 2.12
.80 .025 .032 2.87
Recessive .05 .20 .025 .378 1.58
.50 .025 .229 2.54
.80 .025 .180 3.45
a The sib recurrence-risk ratio ls is the recurrence risk to a sib of
an affected individual divided by the population prevalence (Risch
1987).
a related allele-pooling strategy may still result in
increased power. In particular, we may carry out m
tests, one per allele. In test i, alleles 1, 2,) , i
are pooled together and are contrasted1, i 1,) , m
with allele i to form a two-allele test. As the overall test
statistic, we choose the maximum of these m two-allele
test statistics (Schaid 1996). This strategy should provide
increased power for the case in which a single allele is
(primarily) responsible for the disease-marker associa-
tion. The flexibility of the permutation framework
makes the proper accounting for this maximization in
assessing significance straightforward, since the same
procedure can be carried out for each permutation of
the data. This is important, since by ignoring this max-
imization we could severely overestimate the evidence
for association.
Simulation Study
To verify that the permutation-testing framework re-
sults in the correct nominal significance level and to eval-
uate and compare the statistical power for our seven
DSP-based association tests, we carried out a set of
computer simulations. For each simulation condition,
we generated replicate samples of N DSPs (inR  500
most cases, ), under a series of one-locus au-N  400
tosomal disease models with reduced penetrance and
sporadic cases; we also simulated genotypes for a totally
linked codominant genetic marker. For each replicate
sample, we calculated the statistics, generated 10,000
permutations of each sample under the null hypothesis
of no association, and calculated the resulting 10,000
sets of statistics, to allow us to estimate the P value for
each of the tests. For verification of the correct nominal
significance level, we generated data with no difference
in allele frequencies in affected and unaffected individ-
uals; to assess statistical power, we generated data in
which one marker allele was positively associated with
disease.
For the disease locus, we assumed two alleles, D and
d, with frequencies p and q ( ), respectively, andp q  1
penetrances , not all equal. We0 X f X f X f X 1dd Dd DD
simulated dominant ( ), recessive (f ! f  f f dd Dd DD dd
), and additive [ ] models. Forf ! f f  (f  f )/2Dd DD Dd dd DD
the results reported, we chose a population prevalence
and an attributable2 2K  q f  2pqf  p f  .05dd Dd DD
fraction ; the AF is the propor-AF  (K f )/K  .50dd
tion of disease prevalence that may be ascribed to the
presence of the disease-predisposing genotype(s). We
chose penetrances , .50, and .80 for the pre-f  .20DD
disposing genotype. For the dominant, recessive, and
additive models with three free parameters, p, fdd, and
fDD, fixing K,AF, and fDD uniquely determined themodel.
The sporadic rate for all models, andf  K(1  AF)dd
the disease allele frequency p  1 [(f  K)/(f DD DD
, , and ,1/2 1/2f )] (K f )/(f  f ) [(K f )/(f  f )]dd dd DD dd dd DD dd
for the dominant, additive, and recessive models, re-
spectively. Parameters for the disease models are pre-
sented in table 2. Additional analyses were done with
or .10 or with or 1.00.K  .01 AF  .20
For the marker locus, we assumed complete linkage
to the disease locus (recombination fraction ). Tov  0
allow for disease-marker association, we assumed that
marker allele 1 was positively associated with disease,
with all other marker allele frequencies proportionately
reduced in affected individuals. We simulated markers
with six codominant alleles and population frequencies
.40, .20, .10, .10, .10, and .10 (heterozygosity H 
) and markers with two codominant alleles and fre-.76
quencies .40 and .60 ( ), .20 and .80 ( ),H  .48 H  .32
or .10 and .90 ( ). These simulations allowed usH  .18
to compare results for two- and multiple-allele markers
and to assess the increased power due to a prechosen
comparison.
In each simulation case, we set haplotype frequencies
to yield an allele-frequency difference of C between ran-
domly selected affected and unaffected individuals. To
assess the statistical power of our tests, generally we set
; to verify that our permutation-testing frame-C  .15
work resulted in appropriate significance levels, we set
. For recessive models with andC  .00 f  .20 C DD
, we excluded the two cases of markers with asso-.15
ciated allele frequency of .10, since this combination of
parameters would have resulted in negative haplotype
frequencies. To assess the impact of sample size and dif-
ferences in allele frequencies between affected and un-
affected individuals, we also analyzed data on 50–2,000
DSPs for the dominant model with prevalence .05 and
penetrance .50, a linked marker with allele frequencies
.40 and .60, and , .10, or .15.C  .05
ApoE and Alzheimer Disease
To illustrate the use of our DSP-based tests for as-
sociation, we applied them to data on 112 DSPs from
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Table 3
Power Estimates for DSP Tests: Dominant Model with fDD  .50
ASSOCIATED
MARKER ALLELE
FREQUENCY AND
TEST STATISTIC
POWER, BY NO. OF MARKER ALLELES
Six Six (Pooled) Two
.40
AC1 .718 .812 .918
AC2 .860 .860 .918
GC1 .224 .670 .756
GC2 .276 .502 .710
Gs .090 .792 .826
As .380 .694 .908
Aws .598 .812 .918
.20
AC1 .854 .918 .986
AC2 .914 .944 .986
GC1 .342 .804 .920
GC2 .428 .834 .962
Gs .148 .914 .956
As .656 .866 .984
Aws .768 .914 .986
.10
AC1 .980 .992 1.000
AC2 .988 .994 1.000
GC1 .636 .970 .996
GC2 .702 .988 1.000
Gs .276 .988 1.000
As .930 .990 1.000
Aws .946 .994 1.000
NOTE.—Estimated statistical power (based on 500 simulation rep-
licates each) at significance level , for 400 DSPs, with asso-a  .001
ciated marker-allele-frequency difference of between affectedC  .15
and unaffected individuals. For a detailed description of the statistical
tests and genetic models, see Methods.
100 unrelated families ascertained for the presence of
one or more individuals with Alzheimer disease and
typed for the ApoE polymorphism. ApoE has three com-
mon alleles, e2, e3, and e4, with frequencies of ∼.08, .77,
and .15, respectively, in the general population (Uter-
mann et al. 1980). Increased numbers of the e4 allele
result in an increased risk of Alzheimer disease (Corder
et al. 1993; Saunders et al. 1993), whereas presence of
the e2 allele appears to reduce Alzheimer disease risk
(Corder et al. 1994).
Results
Size and Statistical Power
We began by simulating data for the 12 possible com-
binations of three disease models (dominant, additive,
and recessive with ) and four genetic markerf  .50DD
types (the six-allele marker and each of the three two-
allele markers) under the null hypothesis of no disease-
marker association. For each combination, we compared
the observed distribution of the estimated P values to
that expected for a uniform distribution on the interval
(0, 1). There was good agreement for all simulation con-
ditions as well as for the data aggregated over all 12
analyses (data not shown).
Next, we generated data, under each of the 52 disease
model–genetic marker combinations (nine disease mod-
els by six marker types, less two combinations that
would have resulted in negative haplotype frequencies),
for parameter values that resulted in a difference of
in the frequency of the associated marker inC  .15
randomly selected affected and unaffected individuals.
For each of these 52 simulation conditions, we estimated
the power of each of our tests to detect the disease-
marker association. To compare the statistical power of
the different tests, we estimated the power at significance
levels .05, .01, and .001. We then used logistic regression
to test for differences in the power estimates among the
seven tests.
Table 3 presents power estimates at significance level
a  .001, for 400 DSPs, for the dominant model with
penetrance and for which the allele with pop-f  .50DD
ulation frequency .10, .20, or .40 is associated with dis-
ease. For all marker types, the DAT based on AC2 had
the highest power to detect genetic association. This test
stood alone as the most powerful test for the six-allele
marker, with or without pooling, and was tied to the
tests based on AC1 and Aws for the two-allele markers.
For all tests, power was greater for two-allele markers
(or, equivalently, for a prechosen comparison), and pool-
ing of alleles tended to be a useful strategy, particularly
for the genotype-based statistics. Given a constant allele-
frequency difference C between affected and unaffected
individuals, evidence for association was stronger when
the associated allele was rare or, equivalently, when given
a larger relative risk for the disease-marker allele
association.
Repeating the analyses described in table 3 with any
combination of genetic model (dominant, additive, or
recessive), penetrance value , .50, or .80, as-f  .20DD
sociated marker allele frequency .10, .20, or .40, or test-
ing at significance level or .05 resulted in qual-a  .01
itatively the same conclusions. This is illustrated in table
4, which ranks the powers of the various tests (at a 
) separately by disease model and marker type: two-.001
allele marker data or six-allele marker data with or with-
out pooling of alleles, combined over the various marker
allele frequencies. Horizontal lines above the test names
indicate tests that had power estimates that were indis-
tinguishable at the level, as tested by logistica  .05
regression. Again, the DAT based on AC2 is at least tied
for most powerful in each case considered. For two-allele
markers, tests based on AC1 and Aws are of identical
power to AC2; for six-allele markers without pooling,
these tests are next best after the test based on AC2,
whereas, in the six-allele case with pooling, these two
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Table 4
Comparison of Statistical Power for the DSP Association Tests
NO. OF
MARKER
ALLELES
GENETIC
MODEL
TEST STATISTIC, RANKED BY POWER
1 2 3 4 5 6 7
Six Dominant AC2 AC1 Asw As GC2 GC1 Gs
Additive AC2 AC1 Asw As GC2 GC1 Gs
Recessive AC2 AC1 Asw As GC2 GC1 Gs
Six (pooled) Dominant AC2 Gs AC1 Asw As GC1 GC2
Additivea AC2 Asw AC1 Gs As GC1 GC2
Recessive AC2 Asw AC1 Gs As GC1 GC2
Two Dominant AC2  AC1  Asw As Gs GC1 GC2
Additive AC2  AC1  Asw As Gs GC2 GC1
Recessive AC2  AC1  Asw As Gs GC1 GC2
NOTE.—Horizontal lines indicate those tests with power estimates at a  .001
that were not significantly different from those at . See Results.a  .05
a Powers for Asw and AC1 and for Gs and AC1 were not distinguishable at the
level, but powers for Asw and Gs were distinguishable.a  .05
tests and the test based on Gs rank next. Qualitatively
similar results were also obtained for analyses of data
with or .10, or 1.00, or orK  .01 AF  .20 C  .05
.10 (data not shown). The fact that AC2, AC1, and Aws
result in tests of identical power for two-allele markers
in all cases considered, even though their actual statis-
tical values differ, is explained by their identical rankings
for the different permutations of the data. We have no
explanation of why these ranks are identical for two-
allele markers nor of why they are not identical for
markers with more than two alleles.
Figure 1 displays the strong effect of sample size and
the allele-frequency difference C on the power to detect
an association for AC2, in the case of a dominant disease
locus with 50% penetrance and a linked marker with
population allele frequencies .40 and .60. Small values
of C require very large sample sizes, to achieve even
modest power. The sample size required to attain a fixed
power appears to increase by a factor of at least x2 when
C decreases by a factor of x.
Effect of Misclassification
Misclassification of genetically predisposed individu-
als as unaffected will tend to decrease evidence for as-
sociation. Such genotypic misclassification may occur
due to misdiagnosis or if a genetically predisposed in-
dividual has not yet progressed to disease or has gone
into remission. At its most extreme, this misclassification
would be equivalent to selecting sib pairs in which one
sib is affected and the other is selected at random with
respect to disease phenotype.
To assess the effect of this extreme degree of misclas-
sification, we resimulated data for the 52 genetic models,
under this sampling design, and compared allele-fre-
quency differences between the affected and other sibs.
For these models, allele-frequency differences for the af-
fected and other sibs (as a proportion of the allele-fre-
quency differences for DSPs) were 91%–93%,
84%–89%, and 77%–86% for the 20%, 50%, and
80% penetrance models, respectively. These results sug-
gest that misclassification will have only modest effect
on power, particularly since misclassification generally
will not be this extreme. It also suggests that if verifying
that a sib truly is unaffected is difficult or expensive, sib
pairs in which one sib is known to be affected and the
phenotype information regarding the other sib is equiv-
ocal might provide a reasonable design. This will be less
true if a single locus with high penetrance has strong
influence on disease risk.
Application: ApoE and Alzheimer Disease
To further illustrate the use of our DSP-based tests,
we applied them to 112 Alzheimer disease DSPs con-
structed from 100 independent families ascertained for
at least one affected individual. In nuclear families with
multiple sibs, we included the oldest unaffected sib and
a random affected sib; in families with two or more
sibships, we selected one DSP per sibship. By choosing
the oldest unaffected sib, we hoped to minimize mis-
classification owing to the unaffected sib later becoming
affected.
Table 5 displays the genotype table for the DSPs and
the allele counts for the affected and unaffected sibs,
under both allele-counting schemes. For example, the
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Figure 1 Power of the DAT statistic AC2. Power curves for associated allele-frequency differences, between unrelated affected andunaffected
individuals, of , .10, and .15 (from right to left), for a dominant model with 50% penetrance (sib recurrence-risk ratio ) andC  .05 l  3.23s
a linked two-allele genetic marker with population allele frequencies .40 and .60.
number of e4 alleles counted for affected sibs, under dis-
cordant-alleles scheme 2, was 2 23 2 # 2 1
. As expected, the genotype table ap-2 # 6 7  49
pears to be asymmetric. Both sets of counts show a clear
excess of e4 and a deficit of e2 and e3 in affected sibs,
relative to unaffected sibs (table 5).
Because of the small number of alleles, , andm  3
the sparseness of the genotype table, only 2 # 3 #
genotype tables3 # 2 # 2 # 28 # 7 # 10  141,120
are consistent with the observed numbers of genotype
pairs. Therefore, we evaluated P values by both exact
and Monte Carlo methods, the latter based on
100,000,000 permutations of the data (table 6). These
P values show excellent agreement and demonstrate very
strong evidence for association between ApoE and Alz-
heimer disease. As expected on the basis of our simu-
lation results, the allele-based tests generally performed
better than the genotype-based tests. Interestingly, for
this example, the tests based on AC1 and Aws had the
smallest P values, although not much smaller than those
for the tests based on As or on AC2. Pooling alleles e2
and e3 resulted in somewhat stronger evidence for as-
sociation for Gs (probably owing to the smaller number
of terms in the genotype-pair table), and slightly less
evidence for the allele-counting statistics (probably ow-
ing to the loss of information that had previously been
provided by allele e2). Note that, given the sparseness of
the genotype table for these data, use of the large-sample
approximation for the distribution of Gs would be
2x
inappropriate.
Despite the strong evidence for association, these data
also illustrate the overmatching inherent in the DSP de-
sign. Although the e4 allele frequency of 64/224 ≈ .29
in the unaffected siblings is less than the frequency of
in the affected sibs, it still is substantially107/224 ≈ .48
greater than the general population frequency of .15
(Utermann et al. 1980). Contrasting only those alleles
that are discordant between affected and unaffected sibs
by use of the DAT results in a much larger difference in
the frequency of e4 in affected ( ) and unaf-49/57 ≈ .86
fected ( ) sibs but at the cost of excluding6/57 ≈ .11
nearly 75% of the data.
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Table 5
ApoE Genotype and Allele Counts and Statistics for
the Alzheimer Disease DSPs
DSP GENOTYPE COUNTa
Unaffected-Sib Genotype
Affected-Sib
Genotype e2e2 e2e3 e2e4 e3e3 e3e4 e4e4
e2e2 0 0 0 0 0 0
e2e3 0 0 0 0 0 0
e2e4 0 0 1 0 0 0
e3e3 0 1 0 22 4 0
e3e4 0 2 1 23 34 2
e4e4 0 2 1 6 7 6
DSP ALLELE COUNT
e2 e3 e4
All alleles:b
Affected sibs 1 116 107
Unaffected sibs 8 152 64
Discordant alleles:c
Affected sibs 0 8 49
Unaffected sibs 7 44 6
a ; and pooled .G  29.15 G  26.81s s
b ; and pooled .AC  21.09 AC  17.491 1
c ; and pooled .AC  65.54 AC  67.242 2
Table 6
Association Test–Statistic Values and P Values for ApoE and Alzheimer Disease
TEST
STATISTIC
ALL ALLELES BEST TWO ALLELES
Value
Permutation
P Valuea
Exact
P Value Value
Permutation
P Valuea
Exact
P Value
AC1 21.09 1 # 10
8 .69 # 108 17.49 3 # 108 3.96 # 108
AC2 65.54 3 # 10
8 4.17 # 108 67.24 6 # 108 5.31 # 108
GC1 22.62 4 # 10
8 4.00 # 108 18.69 21 # 108 20.25 # 108
GC2 42.24 89 # 10
8 84.22 # 108 39.39 260 # 108 254.48 # 108
Gs 29.15 369 # 10
8 337.23 # 108 26.81 88 # 108 77.74 # 108
As 17.97 2 # 10
8 1.29 # 108 10.29 13 # 108 12.58 # 108
Aws 11.76 1 # 10
8 .76 # 108 10.16 3 # 108 3.96 # 108
a Based on 100,000,000 permutations of the data.
Discussion
Introduction
Genomewide association studies are likely to take on
increasing importance in the mapping of genes for com-
plex human diseases (Risch and Merikangas 1996).
Emerging genotyping technologies (e.g., see Chee et al.
1996) are likely, in the near future, to enable the ge-
notyping of large numbers of individuals for a dense
array of genetic markers quickly and at a manageable
cost. Efficient study designs and statistical methods are
needed to ensure that the resulting data are put to ef-
ficient use.
Parent-offspring trio–based methods (Falk and Rub-
enstein 1987; Ott 1989; Knapp et al. 1993; Spielman et
al. 1993; Thomson 1995; Schaid 1996) have been de-
veloped that permit association mapping for diseases
such as insulin-dependent diabetes mellitus (IDDM), for
which parental genotype information can be obtained.
These methods avoid the traditional pitfall of associa-
tion-mapping studies—that is, false positives due to a
poorly matched control sample. In this paper, we have
demonstrated that the DSP design, which has this same
advantage, can be used for association mapping of late-
onset diseases, such as NIDDM, Alzheimer disease, heart
disease, and many forms of cancer, for which trio-based
methods are not ideally suited.
Advantages and Disadvantages of the DSP Design
The DSP design has a number of advantages. DSPs
are generally easy to obtain. Since for most genetic dis-
eases the sib recurrence risk is !.50 and for complex
diseases it usually is much lower, most affected individ-
uals provide a DSP. Thus, affected individuals with an
unaffected sib are usually more representative of the gen-
eral disease population than are affected individualswith
one or more affected sibs. For late-onset diseases, af-
fected individuals with an unaffected sib also tend to be
more representative than affected individuals with living
parents. Risch and Zhang (1995) and Rogus and Kro-
lewski (1996) have also demonstrated the utility of the
DSP design for linkage mapping of quantitative traits
and of qualitative traits with high sib recurrence risks,
respectively.
The DSP design has two disadvantages for the pur-
poses of association mapping: misclassification and over-
matching. Misclassification may occur because of in-
correct diagnosis. It may also occur as a result of reduced
penetrance, if a currently unaffected sib develops disease
in the future; both of these errors result in a reduction
of the power to detect an association. This second sort
of misclassification, in which genetically predisposed in-
dividuals are classified as nonpredisposed, can be min-
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imized by appropriate selection of the DSPs. For ex-
ample, we may select DSPs in which the unaffected sib
is relatively old and, if possible, beyond the typical age
range of disease onset. We used this approach for anal-
ysis of the Alzheimer disease data. In fact, misclassifi-
cation is unlikely to have any real effect unless high-
penetrance alleles play a major role in disease risk (see
Results).
Overmatching is less obvious but probably more se-
rious. Because sibs share (disease) genes, allele-frequency
differences between affected and unaffected sibs are gen-
erally less than between randomly selected affected and
unaffected individuals. For example, given a rare, fully
penetrant autosomal recessive disease with no sporadic
cases and with disease allele frequency p and normal
allele frequency q, randomly selected affected and un-
affected individuals have disease allele frequencies of 1
and , so that the difference in disease allele fre-p/(1 p)
quencies is nearly 1. In contrast, for DSPs, affected sibs
still have a disease allele frequency of 1, whereas un-
affected sibs have a disease allele frequency of ∼ ; this13
difference is ∼ less than for randomly selected affected13
and unaffected individuals. For traits with reduced pen-
etrance and/or sporadic cases, this effect can be more
severe. The lone exception is that of a fully penetrant
dominant disease, for which the disease-allele-frequency
difference in DSPs is essentially the same as that between
randomly selected affected and unaffected individuals,
which is ∼ .12
To assess more generally the impact of overmatching,
we calculated the frequencies P(1FA) and P(1FU) of as-
sociated marker allele 1 in randomly selected affected
and unaffected individuals and the corresponding prob-
abilities P(1FA, DSP) and P(1FU, DSP) for marker allele
1 in the affected and unaffected sibs in a DSP. To do so,
we first calculated the corresponding conditional
marker-genotype probabilities. For a randomly selected
affected individual,
1( ) ( )P g FA K f P g ,g ,M g M DD
gD
where gM and , Dd, or dd are the marker andg  DDD
disease genotypes of the individual, respectively, K is the
population prevalence of disease, and fg is the penetrance
of disease genotype g. The joint probability of these ge-
notypes, P(gM, gD), is easily calculated given the disease-
marker haplotype frequencies and the assumption of
Hardy-Weinberg equilibrium. The conditional
probability of marker genotype gM1 for the affected sib
in a DSP is
1( ) ( ) ( )P g FA, DSP P DSP f 1 fM1 g gD1 D2
g gD1 D2
( ) ( ) ( )#P g , g P g , g /P g ,D1 D2 M1 D1 D1
where gD1 and gD2 are the disease genotypes of the af-
fected and unaffected sibs, respectively. Disease-geno-
type probabilities P(gD1) are specified by Hardy-Wein-
berg equilibrium, and the joint probabilities of the
disease genotypes P(gD1, gD2) and phenotypes P(DSP) for
the two sibs are calculated easily by conditioning on the
number of disease genes the sibs share identical by de-
scent. Analogous expressions hold for an unaffected in-
dividual and an unaffected sib in a DSP.
For the disease models we simulated, the ratio of the
difference in disease allele frequencies between discor-
dant sibs to that between randomly selected affected and
unaffected individuals was 51%–62%; the reduction in
differences was smallest for the 80% penetrance models
and largest for the 20% penetrance models. This re-
duction in apparent association can, of course, be over-
come by increased sample size. However, since at least
a quadratic increase in sample size is required to com-
pensate for a linear decrease in the difference in the allele
frequencies, at least a four-fold sample-size increase is
required, to compensate for a two-fold reduction in al-
lele-frequency differences.
AC2 seeks to minimize this overmatching by including
only those alleles discordant in the affected and unaf-
fected sibs. The cost of this minimization is a concom-
itant decrease in sample size. Under the null hypothesis
of no association, the expected proportion of alleles ac-
tually used can be calculated by conditioning on the
number of alleles the sibs share identical by state, as
; here, is the probability of ge-p  p  p  (p  p ) p3 4 7 2 6 i
notype pair i (table 1). Each probability may in turnpi
be calculated by conditioning on the number of alleles
the sibs share identical by descent. For the marker types
considered in our simulation, this proportion was .35
for the six-allele marker and .21, .15, and .09 for the
two-allele markers with allele frequencies .40, .20, and
.10, respectively. Given an association, disease-discor-
dant sibs will be more marker discordant at a linked
marker locus, so more data will be used.
The reduction in allele-frequency differences is not as
severe for sib trios with two affected individuals as for
DSPs. This was particularly true for the 80% penetrance
models, for which the allele-frequency differences be-
tween affected and unaffected sibs were at least as great
as those between randomly selected affected and unaf-
fected individuals, but it was also true, to a lesser extent,
for the 50% and 20% penetrance models. Thus, asso-
ciation-mapping studies carried out in conjunction with
affected-sib-pair–based linkage studies may have greater
power than those based on a random sample of DSPs.
This gain in information must be weighed against the
cost of data collection and the possibility of reduced
generalizability of the findings.
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Alternative Designs
Alternative designs may be used in an effort to achieve
appropriate matching between affected and unaffected
individuals in an association-mapping study. First, for
traits with sufficiently early onset, one can, in principle,
choose between parent-offspring trios andDSPs, to carry
out family-based tests of association. Because of the
overmatching inherent in the DSP design, trio-based
methods are generally more efficient at testing for dis-
ease-marker association than DSPs; thus, when possible,
trio-based methods should be used.
Second, spouse controls may be used. If spouses are
well matched, this approach is reasonable. However, if
disease prevalence and/or age-at-onset distribution dif-
fers in males and females, this approach is less
appropriate.
Third, one might seek additional sibs in each family
and use trio-based methods on those families for which
parental marker genotypes may be inferred with cer-
tainty. The problem with this approach is that marker-
discordant sibs are more likely to allow inference of pa-
rental genotypes. This approach can lead to systematic
bias in the evidence for association, with the degree of
bias depending on marker allele frequencies (Curtis and
Sham 1995).
Assumptions
We made several assumptions in our simulation study.
First, we assumed between the disease and markerv  0
loci. This assumption is true, or nearly so, for candidate
genes and is likely to be nearly true if a genomewide
association study is undertaken with a very dense set of
genetic markers. For a less dense map, greater distance
between disease and marker loci implies attenuation of
the degree of association and the need for a larger
sample.
Second, we assumed that a single marker allele was
positively associated with disease, with all other marker
allele frequencies proportionately reduced in affected in-
dividuals, and we found our allele-pooling strategy to
be effective in this situation. The assumption of a single
disease-associated marker allele may be approximately
true for isolated populations and/or rare diseases, but it
is likely to be an oversimplification for complex diseases,
particularly in outbred populations. Given multiple dis-
ease-associated marker alleles, the allele-pooling strategy
we employed could actually reduce power, as was the
case for the allele-counting statistics in the Alzheimer
disease example. One might consider other allele-pool-
ing strategies. For example, we might choose the best
subset of alleles for the purpose of generating the strong-
est evidence for association; given m alleles, there are
such subsets. Correcting for multiple tests canm12  1
still be accomplished in the permutation-testing frame-
work, although this very general approach is likely to
have reasonable power only if the number of alleles m
is small.
How Many Permutations Are Needed?
In our simulation study, we used only 10,000 data
permutations to estimate significance levels. This rela-
tively small number was dictated by our desire to sim-
ulate a large number of replicate samples for a large
number of different disease models and genetic markers.
For an actual data analysis, as in our Alzheimer dis-
ease–ApoE example, we would either compute the exact
P value or use many more permutations in an effort to
estimate the P value to a desired level of accuracy.
A simple approach is to choose a fixed number of
permutations R in advance, so that for a particular P
value p, the proportional error in estimating p would
be no greater than some number k with probability at
least . In the case of binomial sampling, this re-1 a
quires that R be no less than for2 2 2 2z (1 p)/pk ≈ z /pk
p near 0, where z is the point of the standard1 a/2
normal distribution. For example, if ,p  .0001 k 
, and , then and ..20 a  .05 z ≈ 2 R ≈ 1,000,000
A more efficient approach would be to sample se-
quentially until the estimated P value is determined with
sufficient accuracy. This approach is particularly relevant
if disease associations are to be tested for many markers.
In most such cases, P values will not be near 0 and will
require only modest numbers of permutations, for ac-
curate estimation. Besag and Clifford (1991) describe
two simple schemes to achieve this end. First, we may
choose to generate permutations of the data until S per-
mutations are obtained that yield a larger test-statistic
value than that for the actual data. Setting for2S  1/k
this open-ended procedure results in a proportional error
in the estimated P value generally Xk; for example,
gives . Second, because computing re-S  25 k ≈ .20
sources are limited and P values will occasionally be
small, we may modify the open-ended procedure to stop
at some maximum number of permutations , evenRmax
if less than S permutations have resulted in test-statistic
values larger than those for the actual data. For either
procedure, the estimated P value is the same as that for
fixed sampling, and the standard error is approximately
the same as that for the fixed-sample estimate of a
proportion.
Two-Allele Symmetry Test Statistics
For markers with two alleles, say 1 and 2, we might
define three additional allele-symmetry test statistics.
The first of these test statistics, A2d, contrasts the num-
bers of affected and unaffected sibs possessing at least
one copy of allele 1. The second, A2r, contrasts the num-
bers of affected and unaffected sibs possessing two cop-
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ies of allele 1. The third, A2dr, is the maximum of A2d
and A2r. A2d seems well designed to detect a disease-
marker association for a dominant or additive disease
allele, A2r to detect a recessive disease allele, and A2dr to
be more generally useful. Given a marker with m 1 2
alleles, each statistic may be computed as the maximum
over all m possible two-allele symmetry test statistics.
Our simulation results suggested that these statistics did
not compare favorably to the others we considered (data
not shown).
Possible Extensions and Future Research
We are currently pursuing several extensions to our
DSP-based association-mapping methods. First, for sib-
ships with affected and/or unaffected sibs,a 1 1 u 1 1
we are attempting to extend our methods to make use
of all available sibs rather than just one DSP. One pos-
sibility is to base our test on all possible DSPs ina # u
each sibship. A second possibility is to construct for each
sibship a weighted DSP, in which the alleles or genotypes
present in the a affected and u unaffected sibs are
given—for example, weights 1/a and 1/u. A third pos-
sibility is to ignore individual DSPs, per se, and to focus
on the sibship as a whole. This approach can easily be
taken, for example, for AC1 but not as obviously for
AC2. Any of these three approaches can be incorporated
by permutation; instead of permuting disease pheno-
types between two sibs, disease phenotypes are permuted
among all sibs.a u
Second, we are seeking to extend ourmethods tomake
use of data on multiple tightly linked markers. This be-
comes particularly relevant once initial evidence for as-
sociation is obtained, as we seek to fine-map the putative
disease gene.
For the sake of simplicity, we have described our DSP-
based tests in the context of Pearson tests of heter-2x
ogeneity and symmetry. In fact, for example, each of
these test statistics could be replaced by the correspond-
ing likelihood-ratio test statistic. Limited simulation
work suggests essentially no differences in size or power
when likelihood-ratio statistics are used in the permu-
tation framework. Similarly, one might choose to use a
log-linear modeling approach to test for symmetry,
quasi-symmetry, or marginal homogeneity (Agresti
1990). The advantage of the current approach is sim-
plicity. The advantage of the log-linear approach is
greater flexibility. For example, log-linear models would
allow for inclusion of covariates and for tests of specific
genetic models such as dominance or recessivity. Stan-
dard statistical packages, such as SAS, BMDP, or S-Plus,
can be used to compute these and related models. A log-
linear model that explicitly models the structure between
the four alleles within each DSP may also be a tractable
option and is one that we are currently investigating.
Conclusion
Our results demonstrate that the DSP design can be
used for association mapping of human genetic diseases.
Such an approach is particularly appropriate given a
late-onset disease for which the parent-offspring
trio–based methods are unusable or inconvenient. Our
comparison of several DSP-based test statistics over a
broad class of genetic models suggests that the DAT
based on a statistic that compares the numbers of non-
matching alleles present in the DSPs was the most pow-
erful test among those we considered. We believe that
this test provides a useful approach to association map-
ping for human genetic diseases.
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